Month: July 2025

Not for distribution to U.S. news wire services or dissemination in the United States BRISBANE, Australia, July 24, 2025 (GLOBE NEWSWIRE) — Adyton Resources Corp. (TSXV: ADY) (FSE: 701GR) (“Adyton” or the “Company”) is pleased to announce that, as a result of strong investor demand, the Company has amended its letter agreement with Clarus Securities Inc. (“Clarus”) and PowerOne Capital Markets Limited (“PowerOne” and, together with Clarus the “Lead Agents”) to increase the size of its previously announced best-efforts private placement of units of the Company (the “Offering”) Pursuant to the upsized deal terms, the Offering will now consist of up to 35,000,000 units of the Company (the “Units”) at a price of $0.40 per Unit (the “Offering Price”) for gross proceeds of up to $14,000,000. Each Unit shall consist of one common share...

WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market. Now in the later stages of device development, CGM+ is Trinity’s new AI-native continuous glucose monitoring (CGM) system, combining multi-sensor data and real-time analytics to meet the evolving demands of AI-powered healthcare and wellness.CGM+ combines sustainability with user-friendly design, featuring a compact wearable and reusable sensor applicator. Unlike traditional CGMs focused solely on glucose monitoring, CGM+ integrates an ultra-thin minimally...

Data presented at the UMDF meeting highlighting first three of expected six subjects and two compassionate use patients provide encouraging results supporting continuation of trial HAIFA, Israel, July 24, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces positive interim results of the ongoing Phase 2 trial of the Company’s lead investigational compound MNV-201 in Pearson Syndrome, a fatal pediatric mitochondrial disease characterized by sideroblastic anemia (a disorder causing abnormal red blood cell development), failure to thrive and exocrine pancreas dysfunction. The interim analysis was presented at the United Mitochondrial Disease Foundation (UMDF) Annual...

LOWELL, Mass., July 24, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI) plans to announce financial results for its third quarter ended July 4, 2025, before market open on Thursday, August 7, 2025. In conjunction with the release, MACOM will conduct a conference call at 8:30 a.m. Eastern Time on Thursday, August 7, 2025, hosted by Mr. Stephen G. Daly, President and Chief Executive Officer, and Mr. John F. Kober, Senior Vice President and Chief Financial Officer. Please visit MACOM’s Investor Relations Website to register for a user-specific access code for the live call or to access the live webcast. A replay of the call will be available within 24 hours and remain accessible by all interested parties for approximately 90 days. About MACOMMACOM designs and manufactures high-performance...

Urban brings extensive experience at the intersection of policy, politics and strategy RESTON, Va., July 24, 2025 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC), the nation’s leading mission integrator, today announced that former senior advisor to President Trump and political strategist David Urban has been appointed to its Board of Directors, effective September 15, 2025. Urban has extensive experience across government, military, legal, private and public sectors, helping companies to navigate public policy and strategic communications challenges, as well as advising on corporate governance, risk management and organizational leadership. He will bring that wealth of expertise to his board position at SAIC. Mr. Urban has been appointed to serve on the Board’s Audit Committee and this increases SAIC’s...

Golar LNG Limited is pleased to announce that it has issued its 2024 Environmental, Social and Governance (“ESG”) report. The report is attached and can also be found on our website. Forward-Looking Statements This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended).  All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negative of these terms and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve...

CHINO, Calif., July 24, 2025 (GLOBE NEWSWIRE) — Karat Packaging Inc. (“Karat” or the “Company”) (Nasdaq: KRT), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced it will release its 2025 second quarter financial results after market close on Thursday, August 7, 2025. The Company will host an investor conference call on the same day.Call Date: Thursday, August 7, 2025Time: 2:00 p.m. PT/5:00 p.m. ETPhone: 877-418-4045 (domestic); 412-317-6745 (international)Conference ID: Karat Packaging Inc.Webcast: Accessible at https://irkarat.com/events-presentations/; archive available for approximately one year   About Karat Packaging Inc. Karat Packaging Inc. is a specialty distributor and manufacturer of a wide range of disposable foodservice...

NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This designation complements CAN-2409’s existing U.S. Food and Drug Administration (FDA) Orphan Drug Designation and FDA Fast Track Designation for the treatment of pancreatic ductal adenocarcinoma (PDAC) awarded to CAN-2409 in April 2024 and December 2023, respectively, and underscores the significant unmet medical need in this disease beyond the U.S. CAN-2409 is an investigational, off-the-shelf, replication-defective...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP) today announced that the Company will release its results for the quarter ended June 30, 2025, after the market closes on Thursday, August 7, 2025. This represents results for the first quarter of the fiscal year ending March 31, 2026. Webcast and Earnings Conference Call Management will host a webcast and conference call on Thursday, August 7, 2025, at 5:00 pm ET to discuss the Company’s results for the first quarter of the fiscal year ending March 31, 2026. The webcast will be made available on the Shareholders section of the Company’s website at https://shareholders.stepstonegroup.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register. A replay will also be available on the shareholders...